Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Sep;31(9):1403–1405. doi: 10.1128/aac.31.9.1403

In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.

J A Bosso 1, B A Saxon 1, J M Matsen 1
PMCID: PMC174950  PMID: 3118798

Abstract

The in vitro activity of aztreonam combined with tobramycin and with gentamicin was assessed in 78 clinical isolates of Pseudomonas aeruginosa and 11 clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis. Synergy was detected in 56.4% of P. aeruginosa isolates and 60% of P. cepacia isolates with the aztreonam-tobramycin combination and in 49.3% of P. aeruginosa isolates and 81.8% of P. cepacia isolates with the aztreonam-gentamicin combination. No antagonism was observed. These combinations merit clinical evaluation in the treatment of patients with cystic fibrosis.

Full text

PDF
1403

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronoff S. C., Klinger J. D. In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis. Antimicrob Agents Chemother. 1984 Feb;25(2):279–280. doi: 10.1128/aac.25.2.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bosso J. A., Black P. G., Matsen J. M. Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J. 1987 Apr;6(4):393–397. doi: 10.1097/00006454-198704000-00010. [DOI] [PubMed] [Google Scholar]
  3. Friis B. Chemotherapy of chronic infections with mucoid Pseudomonas aeruginosa in lower airways of patients with cystic fibrosis. Scand J Infect Dis. 1979;11(3):211–217. doi: 10.3109/inf.1979.11.issue-3.07. [DOI] [PubMed] [Google Scholar]
  4. Gold R., Overmeyer A., Knie B., Fleming P. C., Levison H. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr Infect Dis. 1985 Mar-Apr;4(2):172–177. doi: 10.1097/00006454-198503000-00012. [DOI] [PubMed] [Google Scholar]
  5. Jackson M. A., Kusmiesz H., Shelton S., Prestidge C., Kramer R. I., Nelson J. D. Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis. 1986 Jul-Aug;5(4):440–443. doi: 10.1097/00006454-198607000-00014. [DOI] [PubMed] [Google Scholar]
  6. Jacobus N. V., Ferreira M. C., Barza M. In vitro activity of azthreonam, a monobactam antibiotic. Antimicrob Agents Chemother. 1982 Nov;22(5):832–838. doi: 10.1128/aac.22.5.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jewett C. V., Ledbetter J., Lyrene R. K., Brasfield D. M., Tiller R. E. Comparison of cefoperazone sodium vs methicillin, ticarcillin, and tobramycin in treatment of pulmonary exacerbations in patients with cystic fibrosis. J Pediatr. 1985 Apr;106(4):669–672. doi: 10.1016/s0022-3476(85)80100-1. [DOI] [PubMed] [Google Scholar]
  8. Marks M. I., Prentice R., Swarson R., Cotton E. K., Eickhoff T. C. Carbenicillin and gentamicin: pharmacologic studies in patients with cystic fibrosis and pseudomonas pulmonary infections. J Pediatr. 1971 Nov;79(5):822–828. doi: 10.1016/s0022-3476(71)80401-8. [DOI] [PubMed] [Google Scholar]
  9. McLaughlin F. J., Matthews W. J., Jr, Strieder D. J., Sullivan B., Taneja A., Murphy P., Goldmann D. A. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis. 1983 Mar;147(3):559–567. doi: 10.1093/infdis/147.3.559. [DOI] [PubMed] [Google Scholar]
  10. Michalsen H., Bergan T. Azlocillin in respiratory tract infections with Pseudomonas aeruginosa in children with cystic fibrosis. Chemotherapy. 1980;26(2):135–140. doi: 10.1159/000237895. [DOI] [PubMed] [Google Scholar]
  11. Michalsen H., Bergan T. Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis. Scand J Infect Dis Suppl. 1981;29:92–97. [PubMed] [Google Scholar]
  12. Møller N. E., Høiby N. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Scand J Infect Dis Suppl. 1981;29:87–91. [PubMed] [Google Scholar]
  13. Parry M. F., Neu H. C., Merlino M., Gaerlan P. F., Ores C. N., Denning C. R. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. J Pediatr. 1977 Jan;90(1):144–148. doi: 10.1016/s0022-3476(77)80790-7. [DOI] [PubMed] [Google Scholar]
  14. Permin H., Koch C., Høiby N., Christensen H. O., Møller A. F., Møller S. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):313–323. doi: 10.1093/jac/12.suppl_a.313. [DOI] [PubMed] [Google Scholar]
  15. Prince A. S., Neu H. C. Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Antimicrob Agents Chemother. 1981 Oct;20(4):545–546. doi: 10.1128/aac.20.4.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Scribner R. K., Marks M. I., Weber A. H., Tarpay M. M., Welch D. F. Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Antimicrob Agents Chemother. 1982 Jun;21(6):939–943. doi: 10.1128/aac.21.6.939. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES